XIAP and neoplasm: We showed that the antagonist HM90822B efficiently downregulates XIAP and survivin in human EGFR-overexpressing NSCLC cells and demonstrated that this downregulation contributes to enhance cell cycle arrest and apoptosis, even to regress tumor growth in vivo.